FOLH1 and prostate cancer: Recently, we developed a PSMA nomogram to calculate the probability of finding nonlocalized disease on PSMA PET/CT in patients who appear to have cN0M0 disease on conventional imaging.8,9 In this study, we evaluated the significance of the PSMA nomogram (and, by proxy, PSMA PET/CT itself) on long-term, clinically meaningful end points (including distant metastasis [DM], prostate cancer–specific mortality [PCSM], and overall survival [OS]) using internal validation, external validation, and comparison with existing risk-stratification models.